InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 2929

Monday, 05/06/2024 5:41:01 PM

Monday, May 06, 2024 5:41:01 PM

Post# of 3019
ENTA updated corporate slides (5/6/24)

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

The latest version of the slide set is almost identical to the previous version (from 3/13/24); the differences are:

• Slides 3 and 7 have updated financial info from FY2Q24 (ending 3/31/24).

• Slide 37, which shows 2024 news flow, has two small changes: 1) Data from the Zelicapavir (f/k/a EDP-938) RSVPEDs study is expected in 2H24 rather than 3Q24; and 2) Selection of a lead candidate in the CSU program is expected in 4Q24 rather than simply 2024. There is no specific guidance on the timing of topline data from the RSVHR study, which is recruiting patients in the Southern Hemisphere.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News